Amid the flurry of executive orders, chain saws and performative policymaking, regulatory progress and adverse developments in global health persist. We share perspective on biological weaponry in the time of AI, an update on dual-use biologics rules and pending changes, a discussion of the emergence of China in drug discovery, and efforts to reduce drug prices which may lead to new export controls.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
If you are a current subscriber, and had an account on our previous site, you already have an account. If you have not yet logged into our new site, click here to reset your password.
Otherwise, click here to view your options for subscribing.
Please log in to continue |